Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

In this study, 60% of patients with alopecia totalis showed partial hair regrowth after being treated with triamcinolone acetonide injections, with one patient achieving complete regrowth and responding well to further immunotherapy.

In this study, tacrolimus was as effective as clobetasol propionate in treating alopecia areata, suggesting it can serve as an alternative therapy option.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This study found that co-drugs synthesized from hydroquinone and tranexamic acid improved skin targeting and deposition, with reduced irritation and enhanced efficacy for treating hyperpigmentation.

In this study, withdrawal of baricitinib therapy in patients with severe alopecia areata who had achieved hair regrowth led to a loss of benefit in almost all patients, suggesting that continued treatment is necessary to maintain hair regrowth.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

In this randomized, controlled, clinical trial, the researchers found that injectable botulinum toxin did not promote hair growth in men with androgenetic alopecia over 12 or 24 weeks, showing no benefit in improving hair density compared to placebo.

Thoracic medial branch block may be a simpler and effective alternative to thoracic vertebroplasty for pain management.

This study found that oral baricitinib was more effective than methotrexate in treating severe alopecia areata, with significant improvements in SALT scores over six months.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

Botulinum toxin-A may increase hair growth and reduce hair loss in men with baldness, and injecting near blood vessels can improve pain relief and last longer.

Tacalcitol ointment effectively improves bilateral nevus comedonicus.

This study found that one session of intradermal botulinum toxin type A injection decreased scalp sebum secretion and perception of greasiness more effectively than saline for up to 3 months.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

In this study, researchers found that type A botulinum toxin injections can reduce hypertrophic scars effectively, though more high-quality studies are needed to confirm the precision and stability of these therapeutic effects.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

In this case study, Botulinum toxin type A injections were associated with improved hair growth and scalp condition in a patient with radiation-induced alopecia, though the mechanisms remain speculative.

This study found that RADA-PRG hydrogels enhanced skin-derived precursor cell proliferation and improved hair follicle neogenesis in mice, suggesting potential use as a scaffold material in tissue engineering.

In this report, two adult patients with Tatton-Brown-Rahman syndrome exhibited new cardiac features, such as atrial fibrillation and ventricular and atrial dilatation, highlighting the importance of cardiovascular follow-up in adults with this condition.

This study found that approximately 85% of adults with severe alopecia areata who responded to baricitinib at 52 weeks maintained their improvement over a span of four years.

This study found that DEB-BACE combined with systemic chemotherapy was more effective than chemotherapy alone for unresectable lung squamous cell carcinoma, reducing side effects and improving survival rates.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This study suggests that while subcutaneous Botulinum Toxin Type A may offer short-term symptom improvement for female pattern hair loss, its effectiveness does not extend beyond three months.

This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.